A team from Philadelphia, Pennsylvania, USA, examined the potential efficacy of rosiglitazone, a ligand for the g subtype of peroxisome proliferator-activated receptors (PPARs), as a therapy for active ulcerative colitis.
Previous research has demonstrated that ligands for the g subtype of PPARs reduce inflammation in two different murine models of colitis.
A total of 15 patients with mild to moderately active ulcerative colitis, despite therapy with 5-aminosalicylic acid compounds, were enrolled in an open-label study of rosiglitazone (4 mg given orally, twice daily) for 12 weeks.
Of these, 13 patients were receiving concomitant therapy with corticosteroids and/or immunomodulator medications.
|27% of UC patients achieved clinical remission following treatment with rosiglitazone.
| American Journal of Gastroenterology |
Disease activity was measured with the Disease Activity Index.
After 12 weeks of therapy, 4 patients (27%) had achieved clinical remission, of whom 3 (20%) also had an endoscopic remission.
The researchers found that 4 additional patients (27%) had a clinical response without achieving remission.
In addition, 2 patients were hospitalized with worsened disease activity, and 1 patient was withdrawn for nephrotic syndrome.
Dr James D. Lewis, of the University of Pennsylvania School of Medicine in Philadelphia, concluded on behalf of his colleagues, "These data suggest that ligands for the g subtype of PPARs may represent a novel therapy for ulcerative colitis.
"A double blind, placebo-controlled, randomized trial is warranted."